Literature DB >> 7506644

Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases.

S Takano1, M Omata, M Ohto, Y Satomura.   

Abstract

The incidence of posttransfusion hepatitis and "fulminant" hepatitis was investigated by a plan devised at our hospital in December 1982. Of 2959 blood recipients between January 1982 and December 1988, 504 (22.5%) developed posttransfusion hepatitis, with a mean transfusion volume of 10.2 units. Of the 504 cases of posttransfusion hepatitis, "icteric" (T-Bil > 2.0 mg/dl) and "overt icteric" hepatitis (T-Bil > 5.0 mg-dl) developed in 111 cases (22.0%) and 28 cases (5.6%), respectively. Of the 28 overt icteric hepatitis cases, 13 (2.8%) were thought to be true overt icteric posttransfusion hepatitis because the icterus was caused by other reasons in the other 15 cases (seven neonatal jaundice, four hemolytic anemia, one radiation hepatitis, one halothane-induced hepatitis; two other cases were excluded because chronic liver disease was diagnosed by imaging procedures despite serum ALTs in the normal range before transfusion). The anti-HCV serostatus was investigated in five of the 13 true overt icteric posttransfusion hepatitis patients using blood specimens taken 180 days or more following the onset of posttransfusion hepatitis. Anti-HCV seroconversion occurred in three of the five cases (60%). HCV seroconversions were not seen in the cases in which the icterus was due to other reasons.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506644     DOI: 10.1007/bf02090056

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Antibodies to hepatitis C virus in non-A non-B fulminant viral hepatitis.

Authors:  M Yoshiba; K Sekiyama; Y Iwamura; F Sugata; M Sata; R Kumashiro; K Tanikawa; G Yamada; T Tsuji; K Nishioka
Journal:  Gastroenterol Jpn       Date:  1990-04

2.  Hepatitis C virus in fulminant hepatic failure.

Authors:  M Yanagi; S Kaneko; M Unoura; S Murakami; K Kobayashi; J Sugihara; H Ohnishi; Y Muto
Journal:  N Engl J Med       Date:  1991-06-27       Impact factor: 91.245

3.  Prevalence of anti-HCV antibody in blood donors in the Tokyo area.

Authors:  J Watanabe; K Minegishi; T Mitsumori; M Ishifuji; T Oguchi; M Ueda; E Tokunaga; E Tanaka; K Kiyosawa; S Furuta
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

4.  Characterization of a macrophage-tropic HIV strain that does not alter macrophage cytokine production yet protects macrophages from superinfection by vesicular stomatitis virus.

Authors:  R S Kornbluth; J R Munis; P S Oh; P R Meylan; D D Richman
Journal:  AIDS Res Hum Retroviruses       Date:  1990-08       Impact factor: 2.205

5.  Posttransfusion hepatitis in Japan.

Authors:  S Takano; M Omata; M Ohto; Y Satomura
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

6.  Etiology of fulminant viral hepatitis in Greece.

Authors:  G Papaevangelou; N Tassopoulos; A Roumeliotou-Karayannis; C Richardson
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

7.  Immunoglobulin M antibody against hepatitis B core antigen for the diagnosis of fulminant type B hepatitis.

Authors:  M Shimizu; M Ohyama; Y Takahashi; K Udo; M Kojima; M Kametani; F Tsuda; E Takai; Y Miyakawa; M Mayumi
Journal:  Gastroenterology       Date:  1983-03       Impact factor: 22.682

8.  Non-B hepatitis in Japanese recipients of blood transfusions: clinical and serologic studies after the introduction of laboratory screening of donor blood for hepatitis B surface antigen.

Authors:  A Tateda; K Kikuchi; Y Numazaki; R Shirachi; N Ishida
Journal:  J Infect Dis       Date:  1979-05       Impact factor: 5.226

9.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

10.  Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection.

Authors:  I S Sheen; Y F Liaw; C M Chu; C C Pao
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

View more
  1 in total

Review 1.  Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.

Authors:  Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci
Journal:  Hepatol Int       Date:  2015-05-05       Impact factor: 9.029

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.